Skip to main content
. 2016 Apr 13;33:401–416. doi: 10.1007/s10585-016-9791-0

Fig. 4.

Fig. 4

Most promising therapeutic options in prevention (left) and treatment (right) of peritoneal dissemination: 1 anti-integrin α2β1 antibodies; 2 peptide sequences; 3 anti-CD44 antibodies; 4 hyaluronan bound to cytostatic agents; 5 catumaxomab, a trifunctional antibody with binding sites for EpCAM, T-cells and accessory cells. (Color figure online)